Macrophages in Heart Failure with Reduced versus Preserved Ejection Fraction

Research output: Contribution to journalReview article

Abstract

There is a growing number of individuals living with heart failure (HF) with reduced ejection fraction (HFrEF) or preserved ejection fraction (HFpEF). Long-term prognosis remains poor in both cases, especially in HFpEF, which is rising in incidence and lacks effective therapeutics. In both HFrEF and HFpEF, there is evidence that elevated inflammatory biomarkers, implicating innate immune cells such as macrophages, are associated with worsened clinical outcomes. Macrophage subsets are active in both inflammatory and reparative processes, yet our understanding of the causative roles for these cells in HF development and progression is incomplete. Here, we discuss recent findings interrogating the role of macrophages in inflammation and its resolution in the context of HF, with a specific focus on HFrEF versus HFpEF.

Original languageEnglish (US)
JournalTrends in Molecular Medicine
DOIs
StatePublished - Jan 1 2019

Fingerprint

Heart Failure
Macrophages
Biomarkers
Inflammation
Incidence
Therapeutics

Keywords

  • heart failure
  • inflammation
  • macrophage
  • preserved ejection fraction
  • reduced ejection fraction

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology

Cite this

@article{399a194feaa84d04a41ee6d1c0d99c0d,
title = "Macrophages in Heart Failure with Reduced versus Preserved Ejection Fraction",
abstract = "There is a growing number of individuals living with heart failure (HF) with reduced ejection fraction (HFrEF) or preserved ejection fraction (HFpEF). Long-term prognosis remains poor in both cases, especially in HFpEF, which is rising in incidence and lacks effective therapeutics. In both HFrEF and HFpEF, there is evidence that elevated inflammatory biomarkers, implicating innate immune cells such as macrophages, are associated with worsened clinical outcomes. Macrophage subsets are active in both inflammatory and reparative processes, yet our understanding of the causative roles for these cells in HF development and progression is incomplete. Here, we discuss recent findings interrogating the role of macrophages in inflammation and its resolution in the context of HF, with a specific focus on HFrEF versus HFpEF.",
keywords = "heart failure, inflammation, macrophage, preserved ejection fraction, reduced ejection fraction",
author = "Matthew DeBerge and Shah, {Sanjiv J} and Wilsbacher, {Lisa D} and Thorp, {Edward Benjamin}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.molmed.2019.01.002",
language = "English (US)",
journal = "Trends in Molecular Medicine",
issn = "1471-4914",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Macrophages in Heart Failure with Reduced versus Preserved Ejection Fraction

AU - DeBerge, Matthew

AU - Shah, Sanjiv J

AU - Wilsbacher, Lisa D

AU - Thorp, Edward Benjamin

PY - 2019/1/1

Y1 - 2019/1/1

N2 - There is a growing number of individuals living with heart failure (HF) with reduced ejection fraction (HFrEF) or preserved ejection fraction (HFpEF). Long-term prognosis remains poor in both cases, especially in HFpEF, which is rising in incidence and lacks effective therapeutics. In both HFrEF and HFpEF, there is evidence that elevated inflammatory biomarkers, implicating innate immune cells such as macrophages, are associated with worsened clinical outcomes. Macrophage subsets are active in both inflammatory and reparative processes, yet our understanding of the causative roles for these cells in HF development and progression is incomplete. Here, we discuss recent findings interrogating the role of macrophages in inflammation and its resolution in the context of HF, with a specific focus on HFrEF versus HFpEF.

AB - There is a growing number of individuals living with heart failure (HF) with reduced ejection fraction (HFrEF) or preserved ejection fraction (HFpEF). Long-term prognosis remains poor in both cases, especially in HFpEF, which is rising in incidence and lacks effective therapeutics. In both HFrEF and HFpEF, there is evidence that elevated inflammatory biomarkers, implicating innate immune cells such as macrophages, are associated with worsened clinical outcomes. Macrophage subsets are active in both inflammatory and reparative processes, yet our understanding of the causative roles for these cells in HF development and progression is incomplete. Here, we discuss recent findings interrogating the role of macrophages in inflammation and its resolution in the context of HF, with a specific focus on HFrEF versus HFpEF.

KW - heart failure

KW - inflammation

KW - macrophage

KW - preserved ejection fraction

KW - reduced ejection fraction

UR - http://www.scopus.com/inward/record.url?scp=85060996888&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060996888&partnerID=8YFLogxK

U2 - 10.1016/j.molmed.2019.01.002

DO - 10.1016/j.molmed.2019.01.002

M3 - Review article

JO - Trends in Molecular Medicine

JF - Trends in Molecular Medicine

SN - 1471-4914

ER -